The Experts below are selected from a list of 61329 Experts worldwide ranked by ideXlab platform
Andrzej Grzybowski - One of the best experts on this subject based on the ideXlab platform.
-
off label use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
Øystein Kalsnes Jørstad - One of the best experts on this subject based on the ideXlab platform.
-
off label use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
Tomas Bro - One of the best experts on this subject based on the ideXlab platform.
-
off label use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
Magdalena Derebecka - One of the best experts on this subject based on the ideXlab platform.
-
off label use of bevacizumab for wet age related macular degeneration in europe
Graefes Archive for Clinical and Experimental Ophthalmology, 2020Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
-
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Graefe's Archive for Clinical and Experimental Ophthalmology, 2019Co-Authors: Tomas Bro, Magdalena Derebecka, Øystein Kalsnes Jørstad, Andrzej GrzybowskiAbstract:Purpose To analyse current off-label use of bevacizumab for wet age-related macular degeneration (AMD) in Europe. Methods The study was conducted as a combined survey and literature review. It included the 22 most populous countries in Europe. In each country, ophthalmologists with particular knowledge about off-label treatment responded to a questionnaire. Results Answers were obtained from twenty European countries. The off-label use of bevacizumab for wet AMD greatly differed between nations; the bevacizumab proportion varied from non-existent (0%) to very high (97%). There were also large disparities within single countries (e.g. 0–80%), which were attributable to differences in regional decision-making. Both governmental institutions and national ophthalmological societies expressed highly diverging opinions on the use of off-label treatment. Intravitreal administration of bevacizumab had been a matter of legal dispute in several countries. The question about responsibility for off-label therapy mainly remained unanswered. Conclusions There was a highly varying utilization of bevacizumab between European countries. Despite an intention of a consistent approach to medical regulations, Europe has not yet reached a professional or Political Consensus on the ophthalmic off-label use of bevacizumab.
Iain Deas - One of the best experts on this subject based on the ideXlab platform.
-
the search for territorial fixes in subnational governance city regions and the disputed emergence of post Political Consensus in manchester england
Urban Studies, 2014Co-Authors: Iain DeasAbstract:The paper considers the notion that innovation in territorial governance is associated with a set of core neoliberal ideas about local economic development which have come to constitute a new and pervasive Consensus. Through a case study of attempts to construct city-regional institutions in Manchester, England, over a period of 25 years, it attempts to track the themes that have underpinned the development of a local politics of economic development. The paper considers the extent to which evolution of city-regional institutions and policy accord to wider ideas about post-Political forms of governance and the erosion of democracy in cities. It concludes by considering the degree to which this experience is representative of a wider orthodoxy in the governance of local economic development.
-
towards post Political Consensus in urban policy localism and the emerging agenda for regeneration under the cameron government
Planning Practice and Research, 2013Co-Authors: Iain DeasAbstract:The paper explores recent experience of urban policy in England and provides an assessment of its evolution and future prospects under the Cameron government. It explores the contention that urban policy has undergone a fundamental repositioning in which neo-liberal ideas, linked to the emerging localism agenda, have begun to exert a profound shift in the role of the state in formulating and delivering policy. The paper argues that neo-liberal thinking increasingly permeates contemporary policy, but that this exists alongside a residual (but diminishing) emphasis on socio-spatial dimensions of equity. This, the paper concludes, reflects the emergence of a degree of post-Political Consensus around the role for urban policy and the mechanisms for its delivery.
